

## **Fresenius Kabi raises its stake in Pharmatel Fresenius Pty Ltd. to 50.1%**

January 3, 2006

Fresenius Kabi today announced that it increased its stake in Pharmatel Fresenius Kabi Pty Ltd. from 25.1 % to 50.1 % on January 01, 2006. It was part of Fresenius Kabi's plan to further raise its stake in the Australian Joint Venture.

Pharmatel Fresenius Kabi Pty Ltd., was launched September 1, 2004 as a joint venture between Fresenius Kabi and the Australian pharmaceutical company Pharmatel Pty Ltd. Since the successful incorporation of the joint venture, the oncology compounding and gastroenterology business, which was contributed by Pharmatel, has continued to show a strong performance. In parenteral nutrition and anesthesia, which were contributed by Fresenius Kabi, we have also achieved very positive inroads in the Australian market. Due to the well established Pharmatel compounding facilities in Sydney and Melbourne, we have a perfect platform to provide the parenteral nutrition compounding market in Australia with our products.

Pharmatel Fresenius Kabi Pty Ltd., is headquartered in Sydney and employs 95 people.